Augmentation of Endocardial Thromboresistance

Case ID:
C04927
Disclosure Date:
3/6/2006

C04927: Augmentation of Endocardial Thromboresistance


Technical Details:

A critical function of the endocardium is to maintain local thromboresistance by providing an anticoagulant surface. Thrombomodulin, is expressed on the surface of the endocardium endothelial cells and is the key component of the anticoagulant protein C pathway, and thus is critical to maintaining vascular thromboresistance. Endocardial Thrombomodulin expression is significantly reduced by acute heart failure and leads to local microthrombus formation. Conversely, targeted restoration of Thrombomodulin expression is an effective means to prevent microthrombus formation. JHU researchers have identified a novel and important regulator of Thrombomodulin expression in endothelial cells and demonstrated that the ability to prevent the downregulation of Thrombomodulin in endocardial cells.

Looking for Partners:

This technology describes a novel strategy for reducing the risk of stroke in patients with congestive heart failure, valvular heart disease and atrial fibrillation, without subjecting them to the risks of systemic anticoagulation.


Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Augmentation of Endocardial Thromboresistance PCT: Patent Cooperation Treaty United States 12/282,769 8,454,952 12/30/2008 6/4/2013 3/13/2027 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum